By Kamal Choudhury Feb 9 (Reuters) - Privately held Iambic said on Monday it has entered a multi-year partnership worth more ...

After sharing word that it would be prioritizing artificial intelligence to aid discovery work, Takeda Pharmaceuticals has inked a multiyear deal to access Iambic Therapeutics' broad suite of& | ...

Explore AI in drug discovery and its journey from promise to proof in 2025 with significant achievements and challenges faced.

AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda ...

The winners over the next five years” will be the companies that “fully integrate” artificial intelligence into drug ...

AI promised to speed up drug discovery, but the real bottleneck is in clinical trials. This startup is using AI to accelerate ...

Iambic’s physics-informed NeuralPLexer is intended to enhance protein–ligand modeling, enabling broader exploration of ...

AI boosts efficiency in early, high-failure R&D, improving success rates and capital efficiency across biotech and pharma.

Overview AI is speeding up drug discovery by analyzing large biological and chemical data in a short time.Deep learning and AI systems help design new drug mole ...

Advancing proprietary AI discovery of high-bioavailability Oral GLP-1 drug candidates. HOUSTON, Feb. 3, 2026 /PRNewswire/ -- Deep EigenMatics, Inc., a pioneer in high-velocity Artificial Intelligence ...

OpenAI Chief Executive Officer Sam Altman said his company may consider investing in or subsidizing firms that make ...

You can provide a way better UX than this when your app throws errors by providing your own ErrorBoundary or errorElement ...